The effects of portal shunts on intestinal cytochrome P450 3A activity

被引：28

作者：

Rostami-Hodjegan, A ^{[1
]}

Tucker, GT ^{[1
]}

机构：

[1] Univ Sheffield, Div Clin Sci S, Sheffield S10 2TN, S Yorkshire, England

来源：

HEPATOLOGY | 2002年 / 35卷 / 06期

关键词：

D O I：

10.1053/jhep.2002.33215

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：1549 / 1550

页数：2

共 14 条

[1] Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery [J].

Benet, LZ ;

Izumi, T ;

Zhang, YC ;

Silverman, JA ;

Wacher, VJ .

JOURNAL OF CONTROLLED RELEASE, 1999, 62 (1-2) :25-31

[2] Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: Effects of transjugular intrahepatic portosystemic shunts [J].

Chalasani, N ;

Gorski, JC ;

Patel, NH ;

Hall, SD ;

Galinsky, RE .

HEPATOLOGY, 2001, 34 (06) :1103-1108

[3]

Cong D, 2000, DRUG METAB DISPOS, V28, P224

[4] Model-independent estimation of lag times with first-order absorption and disposition [J].

Csizmadia, F ;

Endrenyi, L .

JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (05) :608-612

[5]

Fisher JM, 1999, J PHARMACOL EXP THER, V289, P1143

[6] Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis [J].

Johnson, TN ;

Tanner, MS ;

Taylor, CJ ;

Tucker, GT .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 51 (05) :451-460

[7] Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics:: Use of maximum unbound concentration of inhibitor at the inlet to the liver [J].

Kanamitsu, S ;

Ito, K ;

Sugiyama, Y .

PHARMACEUTICAL RESEARCH, 2000, 17 (03) :336-343

[8]

Lin JH, 1999, PHARMACOL REV, V51, P135

[9]

Paine MF, 1997, J PHARMACOL EXP THER, V283, P1552

[10] Sensitivity of empirical metrics of rate of absorption in bioequivalence studies [J].

Ring, A ;

Tothfalusi, L ;

Endrenyi, L ;

Weiss, M .

PHARMACEUTICAL RESEARCH, 2000, 17 (05) :583-588

← 1 2 →